First Sale Under HHS Peptide Enforcement Discretion: What It Means

What DataMEDS announced, and what it left out

On November 9, 2026, Tampa-based DataMEDS AI (Nasdaq: MEDS) said its subsidiary Corexa Pharmacy completed its first commercial sale of one of the six peptides recommended by FDA's Pharmacy Compounding Advisory Committee (PCAC) at its July 23-24, 2026 meeting: BPC-157, TB-500, KPV, MOTS-c, epitalon and semax¹². The company says the sale was made under HHS's enforcement-discretion policy¹.

What the release does not say matters just as much: it does not name the peptide sold, the price, the quantity or the buyer¹². Interim Co-CEO Gerald Commissiong said the company is still working on its pricing model and will market to prescribing physicians, because compounded medications are prescribed "on a one-to-one basis for individual patients"¹.

The release carries its own caution: the six peptides are compounded drugs, are not FDA-approved and have not been evaluated by FDA for safety or efficacy¹. Its risk factors include possible changes to or withdrawal of the policy, FDA decisions on the 503A bulks list, reliance on suppliers and Nasdaq listing compliance¹. On November 2 the company announced a bulk-substance supply agreement without naming the supplier, saying it intended to begin dispensing in November 2026³. According to StockTitan, on November 9 the stock closed 16.6 % below the previous close, at a market capitalization of about $4 million¹.

This piece builds on our coverage of the policy itself, published November 1: the HHS six-peptide policy. What is new here is the first real sale and what it reveals about legal status.

What "enforcement discretion" means

HHS, not FDA, issued the policy and said it does not intend to take enforcement action against state-licensed pharmacies, federal facilities or licensed physicians that compound these six peptides under section 503A when its conditions are met⁵⁶. The notice was announced October 28-29, with Federal Register publication scheduled for October 30 (FR Doc. 2026-22192)⁴⁷. Comments are due November 13⁴⁶.

It is a decision not to punish, not a permission. Venable writes that the policy "should not be understood as legalizing" the peptides, "creates no rights and is not binding" on HHS or the public, and should not be characterized as a statutory safe harbor⁴. Hyman, Phelps & McNamara call it "conditional enforcement discretion while rulemaking proceeds, not final placement on the Section 503A bulks list"⁸. It lasts until each peptide is addressed in a final rule, and HHS reserves the right to revisit it if a safety signal or quality problem appears⁴⁵.

The ten conditions in plain language

Discretion applies only if all ten conditions are met⁶. In short: the peptide must be in Appendix A and match its Appendix B identity and routes; the bulk substance must come from a section 510-registered facility with a valid certificate of analysis (COA); the original manufacturer, not a repacker or distributor, must be registered, follow CGMP and appear on the COA, and intermediaries must validate and document it; serious adverse events and quality problems must be reported to MedWatch and the states; the label must read "This is a compounded drug product. Not for resale."; the product must contain a single active ingredient; oral forms need documented bioavailability; the only co-packaged device can be a 510(k)-cleared syringe; and the patient-specific prescription requirement stays⁴⁵⁶.

Blends ("no peptide cocktails") and 503B outsourcing facilities are outside the policy⁸¹⁰. Each peptide is also limited to specific routes: semax intranasal only and KPV topical or oral only, for example⁹¹⁰.

What the policy does not do

• It does not add any peptide to the 503A bulks list; that takes a proposed rule, public comment and a final rule, and none has been proposed⁵⁶.
• It does not bind states: boards of pharmacy can still restrict or prohibit these products⁴⁵⁶.
• It does not remove private-litigation risk, and the products remain unapproved drugs⁴⁵.
• It is not a finding of safety or efficacy⁴.
• Adverse-event reporting is a condition of the policy, not a statutory duty; one law-firm analysis questions how it will be enforced⁵.

Why the evidence fight continues

In July the PCAC voted 8-6 (one abstention) for BPC-157, KPV and TB-500; 7-5 for MOTS-c; 8-5 for semax; 7-5 for epitalon; and rejected emideltide (DSIP) 6-7¹². FDA's scientific review team had recommended against all seven¹², citing a lack of efficacy evidence and unknowns about the true risks¹³. RAPS reported that FDA appointed eight new members before the meeting, several reportedly linked to peptide prescribing or promotion¹¹. The Center for Science in the Public Interest (CSPI) argues that every favorable vote came from newly appointed members¹⁴.

HHS says its aim is to "discourage the continued, widespread use" of research-use-only peptides from foreign manufacturers and offer a "more controlled alternative"⁹¹¹, and it described CDER's objections for TB-500, epitalon and semax as "inferential or mechanistic rather than observed"⁹. Critics disagree: Public Citizen urged HHS to rescind the policy¹¹, and the Partnership for Safe Medicines filed a citizen petition asking FDA to stop the compounding of these peptides¹⁵. A compounding-pharmacy journal review summarizes the proposed uses and concerns raised during the committee's review¹⁶.

Questions a physician can ask any pharmacy

A first sale is not an approval, and a listed company's press release is not a regulatory document. The policy's own conditions suggest verifiable questions⁴⁵⁶⁹:

• Who is the original manufacturer, is it section 510-registered, and is its location on the COA?
• Does the COA cover identity, purity, potency and contaminants, and does it match Appendix B?
• Who validated any intermediary supplier, and where is that documented?
• How are adverse events reported to MedWatch and the state?
• Does the state board of pharmacy allow these products?
• Is the product single-ingredient and labeled as required?

A clinician quoted by AJMC warns that gray-market peptides often contain 5 % to 75 % of the labeled amount and some contain arsenic⁹, which is why COAs and traceability sit at the center of the conditions.